Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark E Cooper

Showing results (51-60 of 399) with videos related to

Pageof 40
Sort By:
Frontiers in Bioscience (Scholar Edition)|January 4, 2011
Targeted antioxidant therapies in hyperglycemia-mediated endothelial dysfunctionJudy B de Haan, Mark E Cooper
Diabetologia|April 25, 2015
50 years forward: mechanisms of hyperglycaemia-driven diabetic complicationsNicholas D F Russell, Mark E Cooper
Hypertension (Dallas, Tex. : 1979)|September 6, 2006
Mechanisms of diabetic nephropathy: role of hypertensionSara Giunti, David Barit, Mark E Cooper
The Journal of Clinical Investigation|November 3, 2025
GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesityMark E Cooper, Daniël H van Raalte
Journal of the American Society of Nephrology : JASN|November 25, 2016
Genetics of Diabetic Kidney Disease-From the Worst of Nightmares to the Light of Dawn?Ronald C W Ma, Mark E Cooper
Current Pharmaceutical Design|July 13, 2013
MicroRNA as biomarkers and regulator of cardiovascular development and diseaseShinji Hagiwara, Phillip Kantharidis, Mark E Cooper
Seminars in Nephrology|September 12, 2002
Role of nephrin in renal disease including diabetic nephropathyMark E Cooper, Peter Mundel, Geoffrey Boner
The Lancet. Diabetes & Endocrinology|July 22, 2014
Is there a diminishing return of prior glycaemic control?Nordin M J Hanssen, Mark E Cooper
Angiology|September 30, 2015
Diabetes and Aortic AneurysmJonathan Golledge, Mark E Cooper, Zhonglin Chai
Expert Opinion on Investigational Drugs|April 19, 2005
Agents in development for the treatment of diabetic nephropathyKei Fukami, Mark E Cooper, Josephine M Forbes
Pageof 40

Showing results (51-60 of 399) with videos related to

Sort By:
Pageof 40
Frontiers in Bioscience (Scholar Edition)|January 4, 2011
Targeted antioxidant therapies in hyperglycemia-mediated endothelial dysfunctionJudy B de Haan, Mark E Cooper
Diabetologia|April 25, 2015
50 years forward: mechanisms of hyperglycaemia-driven diabetic complicationsNicholas D F Russell, Mark E Cooper
Hypertension (Dallas, Tex. : 1979)|September 6, 2006
Mechanisms of diabetic nephropathy: role of hypertensionSara Giunti, David Barit, Mark E Cooper
The Journal of Clinical Investigation|November 3, 2025
GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesityMark E Cooper, Daniël H van Raalte
Journal of the American Society of Nephrology : JASN|November 25, 2016
Genetics of Diabetic Kidney Disease-From the Worst of Nightmares to the Light of Dawn?Ronald C W Ma, Mark E Cooper
Current Pharmaceutical Design|July 13, 2013
MicroRNA as biomarkers and regulator of cardiovascular development and diseaseShinji Hagiwara, Phillip Kantharidis, Mark E Cooper
Seminars in Nephrology|September 12, 2002
Role of nephrin in renal disease including diabetic nephropathyMark E Cooper, Peter Mundel, Geoffrey Boner
The Lancet. Diabetes & Endocrinology|July 22, 2014
Is there a diminishing return of prior glycaemic control?Nordin M J Hanssen, Mark E Cooper
Angiology|September 30, 2015
Diabetes and Aortic AneurysmJonathan Golledge, Mark E Cooper, Zhonglin Chai
Expert Opinion on Investigational Drugs|April 19, 2005
Agents in development for the treatment of diabetic nephropathyKei Fukami, Mark E Cooper, Josephine M Forbes
Pageof 40